ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 11/08/22

NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer...

Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) on Monday said it plans to start the first study under its collaboration with Pfizer ( NYSE: PFE ) for its cancer drug candidate ZN-c3. The study is one part of an agreement between the companies, which was previously a...

NEW YORK and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathw...

NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathw...

NEW YORK and SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathw...

Clinical-stage biopharma Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) on Tuesday said it had appointed its co-founder Kevin Bunker as chief scientific officer. "In this new role, (Bunker) will focus on leading Research and Development (R&D) in San Diego, advanc...

NEW YORK and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological path...

Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) appoints with over two decades of medical and biopharmaceutical experienced Carrie Brownstein, MD, as Chief Medical Officer, effective October 3, 2022. For further details see: Zentalis Pharmaceuticals has a new chie...

NEW YORK and SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological path...

Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...